Spritzer Sparkling Adds a Fizzy Twist to Merdeka and Hari Malaysia 2025 with “Kasi Sparkling, Baru Kick!” ACN Newswire

Spritzer Sparkling Adds a Fizzy Twist to Merdeka and Hari Malaysia 2025 with “Kasi Sparkling, Baru Kick!”

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins ACN Newswire

Australian Breakthrough by Cholrem: Cyclodextrin Therapy Reverses Heart Disease, Hailed as Greatest Advance Since Statins

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Champion REIT Announces 2025 Interim Results ACN Newswire

Champion REIT Announces 2025 Interim Results

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.
More
uSMART Group Accelerates Expansion with 12 New Branches ACN Newswire

uSMART Group Accelerates Expansion with 12 New Branches

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers ACN Newswire

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
冠君產業信託公佈2025年度中期業績 ACN Newswire

冠君產業信託公佈2025年度中期業績

- 朗豪坊商場開業20周年「立足本地,引領全球潮流文化」,成品牌進駐熱點,Chiikawa拉麵首間海外分店掀熱潮- 花園道三號於2025年到期的租約已全部處理,續約率維持在高水平- 朗豪坊辦公樓推出結合六大健康維度「6D Wellness」的創新概念,強化其一站式身心健康及生活時尚總匯的市場定位- 香港銀行同業拆息下降節省利息開支,2025年債務成功全額再融資香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 持有花園道三號及朗豪坊物業的冠君產業信託(股份代號:2778)公布截至 2025 年 6 月 30 日止的中期業績。業績摘要 2025上半年2024上半年變動租金收益總額 (百萬港元)1,0291,115- 7.6%物業收益淨額(百萬港元)859954- 10.0%可分派收入(百萬港元)476544- 12.6% 每基金單位分派(港元)0.07010.0809- 13.3% 於2025年6月30日於2024年12月31日變動物業組合總值(百萬港元)58,09860,104- 3.3%每基金單位資產淨值(港元)6.797.16- 5.2%資產負債比率24.5%23.7%+ 0.8pp概覽2025年上半年,儘管全球經濟因貿易緊張局勢和地緣政治衝突而面對重重阻力,但香港的市場氣氛獲多項利好因素支持。股市回暖、香港銀行同業拆息於第二季回落,住宅銷售趨穩定,以及旅遊業穩步復蘇均有助抗衡外部壓力。然而,港人外遊熱潮未退,消費力外移令本地零售市道受壓。與此同時,寫字樓租賃市場依然淡靜,反映供求持續失衡。在此市況下,本信託的可分派收入下跌12.6%至4.76億港元,而每基金單位分派(「每基金單位分派」)則減少13.3%至0.0701港元。冠君產業信託行政總裁侯迅女士(左),冠君產業信託投資及投資者關係總監陸嘉萍女士(右)花園道三號雖然中環整體寫字樓市場的租賃動力仍然疲弱,但隨着金融市場轉趨活躍,我們接到的租賃查詢有所增加,需求主要來自金融相關企業。花園道三號落實引進一批新的租賃面積較小的租戶,包括家族辦公室;而一名現有銀行業租戶亦於物業內擴充。於2025年6月30日,花園道三號寫字樓的出租率為80.7%。該物業的租金收益期內減少5.4%至5.40億港元(2024年:5.71億港元)。我們持續推動續租工作,2025年到期的租約已全部處理完畢且續約率維持在高水平,當中包括多名主要租戶的續租。而2026年到期的租約亦有超過70%已續租。朗豪坊辦公樓報告期內,朗豪坊辦公樓推出名為「6D Wellness」的YouTube頻道,藉此強化朗豪坊辦公樓作為一站式身心健康及生活時尚總匯的市場定位。於2025年6月30日,在該物業的租戶組合中,生活時尚(身心健康)行業租戶佔比達68%。於2025年6月30日,朗豪坊辦公樓的出租率保持在86.9%的穩定水平。我們擴大了共享工作空間的營運規模並增設「Social Wellness Hall」,專為舉辦工作坊及交流活動而設,正好呼應辦公樓推廣身心健康的定位。市場租金繼續面對挑戰,租金收益因而減少9.1%至1.51億港元(2024年:1.66億港元)。冠君產業信託行政總裁侯迅女士朗豪坊商場今年迎接開業20周年的朗豪坊商場,繼續秉持「Stay Local,Trend Global」(「立足本地,引領全球潮流文化」)的願景。透過沉浸式體驗和限定商品,我們成功吸引破紀錄的人潮及推動銷售,並在八月刷新單日人流紀錄。近日,首次進軍香港的時裝品牌BENLAI,以及全城首家以生活風格為主題的期間限定店Umbro均在朗豪坊商場開業,人氣拉麵店Chiikawa Ramen Buta亦選址朗豪坊商場設立首家海外分店,旋即成為高人氣新熱點。於2025年6月30日,商場的出租率維持在99.2%的高水平,目前屬已承諾悉數租出的狀態。消費行為的改變為租戶帶來挑戰,租金收益跌至3.38億港元(2024年:3.78億港元)。分派本信託期內可分派收入下跌12.6% 至4.76億港元(2024年:5.44億港元),而每基金單位分派則減少13.3%至0.0701港元(2024年:0.0809港元)。按2025年6月30日的基金單位收市價2.08港元計算,相當於年度分派率6.7%。資產值於2025年6月30 日,本信託旗下物業組合的估值為581億港元,較2024年12月31日的601億港元減少3.3%。可持續發展我們繼續透過提升氣候抗禦力、建立有意義的聯繫及促進社區福祉,為我們的生態圈創造共享價值。報告期內,花園道三號引入人工智能製冷機組優化系統,全年節省大廈制冷設備的能源用量達6.1%。我們透過「綠『惜』環保約章」計劃,推動寫字樓和零售租戶攜手實現可量化的環保目標。此外,我們舉辦以「創新.啟發.融合」為主題的「冠君產業信託 ESG Gala」,凝聚逾千名租戶和商業夥伴,共同推進可持續營運及共融舉措。展望儘管香港零售業已重拾增長,金融市場亦見反彈,預料本信託於2025年後續期間的整體經營環境依然嚴峻。雖然港元利率回落有助節省利息支出,但續租租金下跌或將持續壓抑租金收益及令分派較去年為低。面對競爭激烈的市場環境,我們將繼續以靈活的營運策略積極應對。有關冠君產業信託(股份代號:2778)冠君產業信託擁有及投資提供租金收入的寫字樓及零售物業。信託主要投資位於優越地點的甲級商用物業。現時擁有花園道三號及朗豪坊兩幢位於香港的地標性物業,並以合資股權形式擁有位於倫敦市中心的 66 Shoe Lane,總樓面面積約300萬平方呎,讓投資者可直接投資於優質甲級寫字樓及零售物業。信託自2023年榮獲全球房地產GRESB可持續的最高五星級別。冠君產業信託管理人乃鷹君資產管理(冠君)有限公司,為鷹君集團的成員。網站: www.championreit.com Copyright 2025 亞太商訊 via SeaPRwire.com.
More
盈立集團積極擴張 開設12間分行 紮根香港新加坡 服務全球投資者 ACN Newswire

盈立集團積極擴張 開設12間分行 紮根香港新加坡 服務全球投資者

香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 由周大福控股戰略入股的uSMART盈立證券欣然宣佈香港落馬洲港鐵站、西九龍高鐵站分行已正式投入服務,涵蓋陸路出入境和高鐵樞紐客戶群。為隆重其事,盈立證券今日在西九龍分行舉行簡單而隆重的開幕儀式,並邀得不少財經界精英出席,令活動生色不少。開幕禮上,盈立證券執行董事李建翰先生 (Neo Lee) 表示:「為提供更便捷的金融服務予區內居民,盈立集團計劃年內於香港及新加坡兩地社區內開設分行,連同總部客戶專區,服務點增至12個,進駐尖沙咀、銅鑼灣、荃灣、上水及上環等核心地區,全面強化區域服務網絡,拉近與本地客戶的距離,提供更貼心的服務。」「作為港資科技券商No.1^,全球超過800,000用戶,盈立證券十分重視提升用戶的投資體驗,是次開立分行不但提供綜合服務,包括投資諮詢、辦理開戶等,還協助長者及初學者處理開戶流程、學習App使用方法等,藉此深化本地市場,滿足客戶對相關服務的殷切需求。」Neo Lee 續說。(左起︰盈立證券業務拓展總監鄧永麟先生、盈立證券香港市場部總監黃曉霖小姐、盈立證券執行董事兼機構業務負責人李建翰先生、盈立證券資產管理兼投研部總監蔣雄先生及盈立證券業務拓展經理林向尊先生)新張期內,前往分行打卡即可獲贈神秘禮品乙份,同時亦可免費享用飲料及手機充電服務,於分行開戶更可額外獲得豐富禮品。為進一步開拓香港市場,盈立證券推出「Trader賬戶」,香港本地客戶專享美港股一世免佣,美股期權0佣優惠。為感謝客戶的支持,uSMART盈立證券亦同時提供多項真全免優惠,不論新客戶或現有客戶,均可享受,絕無取巧,優惠包括:1)IPO 孖展認購0息│現金認購0手續費;2)>100隻港股ETF 0佣0平台費 (當中包括近期投資者熱愛的高息股ETF、虛擬資產相關ETF及指數ETF等);3)月供美股、港股0佣0平台費0存倉費及免代收股息稅以上優惠旨在滿足短線、中線及長線投資策略,讓持有uSMART盈立證券賬戶的客戶均能受惠。Neo Lee在開幕禮上透露,集團正積極增聘人手,擴充香港及新加坡團隊,以支持及推進業務發展,提高本地市場競爭力;而集團旗下的美國辦公室亦正式進駐至世界金融中心-紐約曼哈頓城中心,並將專注於對接對沖基金、家族辦公室及擬赴美上市企業,提供機構經紀、資產配置及投行諮詢等專業服務,鞏固全球金融科技券商領域的領先地位。展望未來,uSMART盈立證券秉持以客為本的理念,為更多本地投資者提供星級投資體驗及優質線下服務,同時亦致力推動金融服務的創新與升級,為全球客戶創造更多價值。^「港資科技券商No.1」是取自捷利金融雲截至2025年5月為止連續超過一年數據, uSMART 盈立證券為香港本地港資互聯網券商月成交總額排行第1。 優惠受條件及細則約束關於uSMART盈立證券:由周大福控股戰略入股的盈立證券是一間領先科技港資券商,成立於2018年,7年來憑藉卓越的戰略規劃和創新能力,致力於將科技與金融深度融合,業務範圍涵蓋證券、資產管理、財富管理等領域,為全球投資者獨家研發了金融證券交易平台uSMART HK APP和uSMART SG APP,分別由盈立證券(香港)和盈立證券(新加坡)提供服務。集團APP支持港股、美股、A股(滬深港通)、新加坡股票、日本股票、英國股票、美股期權、ETF、基金、債券、資管、結構化票據、期貨、加密貨幣、貴金屬、黃金和外匯等多元化的投資交易服務,此外更為超高淨值個人與家族、企業提供度身訂制服務,打造全方位綜合性資產管理解決方案。詳情可瀏覽https://hk.usmartglobal.com/傳媒查詢:黃曉霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亞太商訊 via SeaPRwire.com.
More
康哲藥業(867.HK,8A8.SG)上半年營收淨利雙升 戰略轉型跑出增長新動能 ACN Newswire

康哲藥業(867.HK,8A8.SG)上半年營收淨利雙升 戰略轉型跑出增長新動能

深圳,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 8月18日,康哲藥業發佈2025年中期業績,公司營收和利潤同比均實現增長,戰略轉型成效初顯。報告期內,公司實現營業收入約40.0億元(人民幣,下同),同比增長10.8%。若全按藥品銷售收入計算則營收約46.7億元,同比增長8.9%。實現淨利潤約9.3億元,同比增長3.1%。具體來看,康哲藥業已走出國採陰霾,業績將回歸持續上升軌道。公司主要非國採獨家/品牌產品及創新產品全按藥品銷售收入合計約29.0億元,同比增長20.6%,占總收入比重升至62.1%。公司獨家/品牌產品、創新產品競爭格局良好、增長可預期性強,目前已成為拉動業績向上的主力軍。根據業績公告,公司自2018年起擘畫「新康哲」轉型藍圖,以「產品創新、商業革新、國際拓展」三大戰略為支柱,構建可持續的第二增長曲線。行至2025年上半年,良好的經營業績及創新成果持續落地,證實戰略升級已逐步兌現為硬核戰果。「新產品」戰略推動創新價值兌現 夯實增長後勁立於公司三大戰略之首的「產品創新」戰略,依託「海外授權+國內合作+自主研發」三維創新機制,持續注入高價值短、中、長期管線,成為驅動增長的重要引擎。目前,創新戰略已進入持續收穫期,新產品正不斷釋放商業與臨床價值。截至目前,公司已有5款創新藥成功於中國實現商業化;2025年內,蘆可替尼乳膏和德昔度司他片兩款創新產品亦有望獲批上市。蘆可替尼乳膏是美國FDA以及歐洲EMA批准的首個、也是唯一一個局部JAK抑制劑非節段型白癜風複色產品,有望成為中國獲批上市的首款白癜風治療藥物,將填補市場空白,為中國白癜風患者帶來新希望。此外,阿爾茨海默病新藥ZUNVEYL的中國上市申請(NDA)亦已於今年7月獲受理;消費醫療產品注射用聚左旋乳酸微球填充劑已獲得上市批准,進一步豐富公司多元化產品矩陣。在研創新管線中,已有多款重磅候選藥物進入中國後期臨床開發階段,預計將在未來1-3年內陸續進入商業化,形成持續放量的新動力。其中,合作產品注射用Y-3已完成中國III期臨床,該產品為原創單分子1類新藥,亦為全球唯一進入臨床研究的非肽類PSD95/nNOS解偶聯劑,並有望成為首個治療缺血性卒中並預防卒中後抑鬱焦慮的雙功能腦細胞保護藥物。另一個口服小分子1類新藥ABP-671(URAT1抑制劑)用於治療痛風及高尿酸血症,目前其中國IIb/III期臨床正有序推進中。相較現有主流藥物,該產品有潛力以更低劑量將尿酸降低至更低水平,並具有溶解痛風石的能力,有望為患者提供療效更優、安全性更高的治療選擇。康哲藥業亦持續增厚創新儲備,不斷夯實全鏈條創新實力,以實現創新產品分階段、源源不斷獲批上市。2025上半年,公司新增ZUNVEYL、MG-K10(長效抗IL-4Rα人源化單抗注射液)兩款合作開發創新產品。截至目前,公司累計佈局約40款差異化創新管線,其中約20項為自主研發項目。同步推進「新模式」、「新地域」戰略 拓展多維增量空間根據業績公告,康哲藥業持續推進「新模式-商業革新」戰略,以多元生態鍛造抗週期韌性;並堅定執行「新地域-國際拓展」戰略,以產業國際化出海模式構建多維增長格局。在商業革新戰略下,公司持續聚焦專科領域,同時拓展新零售、新媒體渠道,構建「院內+院外」、「線上+線下」全覆蓋的營銷推廣體系,並持續強化消費醫療產品佈局。公司皮膚健康業務「德鎂醫藥」已在這一具消費屬性的賽道嶄露頭角,自2021年獨立運營以來,已實現皮膚疾病領域適應症覆蓋廣度、皮膚處方藥收入規模的雙重領先,將通過介紹上市、實物分派方式,擬分拆於香港聯交所主板獨立上市,進一步釋放其獨立價值與高成長潛力。國際化方面,2025年7月15日,公司以介紹方式成功於新加坡交易所完成第二上市,「產業國際化」戰略邁入新里程。以新加坡為樞紐,公司構建起覆蓋「研-產-銷」的新興市場全鏈條業務體系。截至目前,商業化平台公司Rxilient已在東南亞、中東、港澳台等地區累計提交近20款藥品和器械註冊申請,涵蓋皮膚科、眼科、腫瘤、自免、中樞神經等領域。蘆可替尼乳膏(白癜風適應症)已在澳門、香港獲批,並已遞交新加坡、台灣註冊申請;靜脈注射用特瑞普利單抗(首個被中國NMPA及美國FDA批准上市的國產抗PD-1單抗藥物)已提交馬來西亞等五國註冊申請;替瑞奇珠單抗注射液、蔗糖羥基氧化鐵咀嚼片亦在香港獲批。同時,公司持股45.0%的聯營CDMO生產工廠PharmaGend,目前已具備片劑、膠囊等口服固體製劑年產10億片的能力,並獲得新加坡HSA頒發的生產許可證、美國FDA cGMP認證及瑞士QP審計通過。PharmaGend鼻噴劑、乳膏、注射劑等新產線的建設正穩步推進中,為國際市場提供高標準生產交付能力。展望未來,「新康哲」增長邏輯有望加速兌現,盈利能力與業績韌性將同步提升。公司正構建以差異化創新為核心、多元生態協同驅動、國際化佈局支撐的增長體系,為高質量發展打開長期空間,為全球患者提供高品質醫藥產品和服務,為股東帶來可持續回報。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平台型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力,其中皮膚健康業務已成爲該細分領域的龍頭企業,帶來專科規模效率。同時,康哲藥業持續深化東南亞及中東區域業務發展,助力高質量持續健康發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More
China BlueChem Reports Revenue of RMB5.850 Billion and Profit of RMB641 Million for 2025 Interim ACN Newswire

China BlueChem Reports Revenue of RMB5.850 Billion and Profit of RMB641 Million for 2025 Interim

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
中海石油化學2025年中期實現收入人民幣58.50億元 盈利人民幣6.41億元 ACN Newswire

中海石油化學2025年中期實現收入人民幣58.50億元 盈利人民幣6.41億元

財務摘要(人民幣億元)截至 6 月 30日止年度2025年中期2024年中期變動收入58.5060.07- 2.61%毛利8.4810.03- 15.45%稅前利潤8.398.99-6.67%本公司擁有人應佔淨利潤6.416.87- 6.70%每股基本盈利 (人民幣元)0.140.15- 6.67% 香港,2025年8月19日 - (亞太商訊 via SeaPRwire.com) - 中海石油化學股份有限公司(「中海石油化學」或「公司」,股份編號:3983) 公佈截至2025年6月30日止日止半年度未經審計之業績。2025年上半年公司實現收入人民幣5,850百萬元,同比微跌2.6%,本公司擁有人權益應佔淨利潤為人民幣641百萬元,同比微跌6.7%。中海石油化學首席執行官饒仕才先生表示:「縱使面對外部環境複雜多變與內部結構調整壓力,公司主要經營指標仍然完成良好。期内,公司繼續強化安全生產管理,積極拓展市場與銷售渠道,深化精益管理;同時,扎實推進穩增長、深改革、提效能各項工作。此外,公司堅持秉持綠色可持續發展理念,甲醇裝置連續十四年獲評石化聯合會『能效領跑者』榮譽稱號,合成氨裝置連續六年蟬聯氮肥協會『水效領跑者』 榮譽稱號,並榮膺第四屆國際綠色零碳節暨ESG領袖峰會『2025 ESG 典範企業獎』,樹立了可持續發展品牌標杆。」生産管理方面,公司持續強化生產經營管控與體系管理,深入踐行綠色發展理念,安全生產形勢總體平穩。期内,海南富島甲醇產量與八所港累計吞吐量均創歷史同期新高,華鶴煤化工化肥裝置實現314天長週期運行,刷新自身紀錄,生產指標表現亮眼。上半年,公司生產尿素96.8萬噸、甲醇78.1萬噸、磷肥及複合肥45.0萬噸、丙烯腈系列產品13.2萬噸。銷售管理方面,面對複雜多變的市場形勢,公司持續深化市場研判,緊貼市場精準定價。通過固化產銷協同周例會機制,優化儲運銜接,保障產品高效流通。同時加大出口創效力度,全面推進拓市增效。上半年,公司銷售尿素99.6萬噸、甲醇72.6萬噸、磷肥及複合肥38.6萬噸、丙烯腈系列產品12.7萬噸。綠色發展方面,上半年公司加速推進重點項目落地,成功產出以城市垃圾為原料的國內首噸綠色甲醇,並獲得國際可持續發展和碳認證(ISCC)。該產品成功應用於國產雙燃料船舶,實現了國內綠色甲醇首次加注。此外,公司實現監測數據統一接入環保資訊系統,污染物排放連續三年100%達標,環保污染事故事件保持為零。其中,大峪口化工磷石膏綜合利用率由61.15%提升至73.09%,超額完成指標要求。展望2025下半年,尿素仍處於產能擴張週期,市場整體將延續「供大於求」格局,三季度受出口窗口期與農需支撐疊加影響,需求較強;進入四季度後,新增產能釋放與需求轉淡形成共振,價格預計持續承壓。磷酸一銨價格或呈高位窄幅震盪態勢,一方面原料成本支撐強勁,另一方面需求端亦有利好因素加持。磷酸二銨市場預計維持穩中整理節奏,三季度國內秋儲與出口需求共振,整體需求旺盛,價格將保持平穩運行;四季度磷肥需求預計整體回落,價格存在回調壓力,但受成本端支撐,整體波動幅度將較為有限。預計下半年,甲醇供應延續寬鬆態勢,受益於國內反內捲及煤製甲醇新建項目政策限制,供需結構有望改善,下游需求或呈階段性回暖,市場整體走勢以震盪為主。丙烯腈方面,供過於求的格局預計將進一步加劇,丙烯腈價格若要出現好轉,需依賴國內主流企業降低裝置負荷。公司首席執行官饒仕才先生表示:「2025年下半年,公司將聚焦完善設備管理體系,保障裝置安全平穩運行,夯實本質安全基礎;同時著力打造品質定位,抓好拓市拓銷,提升營銷創效能力。此外,公司將推進『人工智慧+』行動,加速數智技術與實體經濟的深度融合,推動富碳天然氣利用重點項目研究及強化傳播矩陣管理,持續提升品牌價值。」有關中海石油化學股份有限公司中海石油化學股份有限公司(「中海石油化學」)是專門從事化肥及相關化工産品開發、生産及銷售的上市企業,是化肥産能及産量最大的中央企業,為從事石油和天然氣勘探、開發、生産及銷售的中國海洋石油集團有限公司之子公司。中海石油化學於2006年9月29日在香港聯合交易所主板掛牌上市,股份編號:3983。公司現有生産設施位於中國海南、湖北及黑龍江,總設計年産能達184萬噸尿素、130萬噸磷複肥(磷酸一銨、磷酸二銨和複合肥)、140萬噸甲醇、20萬噸丙烯腈及7萬噸MMA,公司並擁有位於海南省東方市的設計年吞吐能力為1,828萬噸的深水港口。中海石油化學的企業品牌價值持續提升,2025年達72.58億元,創歷史新高。2025年,中海石油化學榮膺第四屆國際綠色零碳節暨ESG領袖峰會『2025 ESG 典範企業獎』。如欲查詢更多公司資料,請瀏覽公司網站 www.chinabluechem.com.cn。 Copyright 2025 亞太商訊 via SeaPRwire.com.
More

Qunabox Group Deliver Strong H1 2025 Performance with Over 30% Growth in Revenue and Gross Profit

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the artificial intelligence (AI) sector emerged as one of the most prominent structural investment themes in capital markets, sparking significant market enthusiasm. The market capitalization of leading companies in multiple AI-related segments saw significant increases, and the overall sector valuation rose markedly. As a result, the AI sector has become a high-prosperity track favored by institutional investors for portfolio allocation.Market analysts expect AI applications to emerge as a breakout sector as artificial intelligence deepens its integration across industries. Companies demonstrating both product innovation and real-world deployment capability are likely to draw heightened investor appetite. Among them, Qunabox Group (00917.HK), with its forward-looking strategic layout in “AI + Consumption Scenarios,” along with sustained high-intensity investment in technology and strong product commercialization capabilities, is poised to stand out in this wave of technology-scenario integration, potentially establishing itself as one of the most promising growth companies in this sector.On August 15, Qunabox Group released its 2025 interim results. In the first half of 2025, the Company achieved robust growth driven by continuous advancements in business model innovation, service capabilities enhancement, industry reputation building, and improved team execution. Leveraging its competitive advantages accumulated through years of sustained investment in AI, Qunabox Group seized the policy-driven opportunities in AI and consumption industries. The Company achieved revenue of RMB676.2 million, representing a year-on-year increase of 31.3%, while gross profit rose to RMB385.5 million, up 37.0% year-on-year, maintaining strong growth momentum and solidifying the Company’s leading position in China’s AI interactive marketing industry.Strategic Upgrade: Comprehensive Industrial Expansion from AI+ Marketing to AI+ Consumption ScenariosIn response to the profound transformation brought by the AI industrial revolution, Qunabox Group has fully upgraded its core strategy to focus on “AI + Consumption Scenarios”. The Company is concentrating on two key application scenarios – AI+ Marketing and AI+ Entertainment – while accelerating innovation in AI-powered services and product development. To support this strategic shift, the Company significantly increased its research and development investment in the first half of 2025 to RMB77.8 million, representing a year-on-year growth of 107.7%. As of 30 June 2025, Qunabox Group has established a robust technological moat, with cumulative registrations of 159 software copyrights and 34 patent applications.In terms of technology research and development, Qunabox Group has built an AI technology middle platform that reinforces its foundational technical architecture. By innovatively adopting a modular design approach, the Company has developed a reusable AI capabilities pool, significantly enhancing research and development efficiency and strengthening the scalability of its technologies across diverse application scenarios. Meanwhile, its self-developed multi-modal neural integrated collaborative engine—the AI-OMNI Engine (AI-Orchestrated Multimodal Neural Integration) —has achieved key technological breakthroughs, successfully empowering the three core layers of “perception, decision, execution,” significantly enhancing edge intelligence and multi-scenario adaptability.Notably, Qunabox Group has also made forward-looking advancements in the field of AI Agent. According to the Company’s 2025 interim report, it has deeply integrated AI Agent technology with its self-developed terminal operation and maintenance (O&M) large model, establishing a more intelligent O&M management system. This technological integration not only enables intelligent task dispatching and automated maintenance guidance, but also drives the transformation of O&M models from traditional “reactive maintenance” to “proactive prevention.” Industry analysts believe this move significantly enhances the professional capabilities and execution efficiency of terminal operation teams, marking a critical step in Qunabox Group’s journey toward operational intelligence. Moreover, it provides solid operational support for the large-scale implementation of the company’s “AI + Consumer Scenarios” strategy.Rapid Unleashing of the “AI+ Marketing” Business Flywheel EffectIn terms of marketing business, Qunabox Group has built a high-growth business flywheel by continuously driving the coordinated evolution of five core elements including product, client, data, technology and operations. In the first half of 2025, Qunabox Group’s marketing service revenue reached RMB568.0 million, representing a year-on-year increase of 37.9%; gross profit was RMB353.3 million, up 43.8% year on year. Among these, revenue from the standardized marketing services segment increased by 34.3% year on year, while revenue from the high-margin value-added marketing services segment grew by 63.1%, effectively boosting the Company’s overall profitability.On the one hand, while maintaining strong and stable partnerships with brand customers, Qunabox Group further tapped into the potential of KA customers by expanding service application scenarios, enriching and optimizing AI interactive marketing products, developing data strategy products, and refining its marketing product portfolio and service pattern, thereby broadening its collaboration with major customers. Leveraging its proprietary AI-OMNI Multi-modal Neural Synergy Engine, the Company has achieved dual breakthroughs in AI digital shopping assistants—enhancing both intelligent interaction capabilities and visual expressiveness—thereby significantly boosting customer engagement and conversion rates at offline terminals. In the first half of 2025, the average revenue per KA customer increased to RMB16.2 million, representing a year-on-year growth of 52.2%, providing strong support for high-quality revenue growth. On the other hand, by leveraging its technological and operational capabilities to advance the modularization of its marketing system, the Company enhanced its flexible combination capabilities between standardized marketing services and value-added marketing service modules, enabling complementary synergy, flexible integration, and efficient reuse between standardized and value-added services.It can be said that Qunabox Group’s “AI + Marketing” strategy has evolved from technological leadership to systematic growth, forging a five-dimensional moat integrating products, clients, data, technology, and operations—laying a robust foundation for sustained future growth.“AI+ Entertainment” Goes Global: Middle East Expansion Marks the Start of Ambitious Worldwide GrowthIn addition to marketing scenarios, Qunabox Group is actively capitalizing on the emerging “emotional consumption” trend in expanding the boundaries of AI entertainment applications. The Company has strategically positioned “AI + Entertainment” as a new frontier, aiming to build world-leading AI-powered indoor entertainment spaces, with the Middle East market as its first stop for global expansion. In the first half of 2025, Qunabox Group established an Overseas Entertainment Division, focusing on the strategic planning, product design, and commercialization of AI indoor entertainment spaces, to further strengthen the execution efficiency and market expansion of this business.Currently, the Division has completed its organizational structure and preparation for the first batch of venues, successfully obtaining the relevant local licenses. At the same time, core tasks such as product design and optimization, software and hardware system development, and the construction of content ecosystems are steadily progressing. Industry experts suggest this move may represent a strategic play in Qunabox Group’s global “IP incubation” initiative. By leveraging AI-generated technology and deep user behavior insights, the Company could develop original virtual characters and interactive experiences that balance local cultural relevance with global appeal. Through cross-media storytelling and digital asset management, these efforts may cultivate high-value original IPs. Such IPs are expected to serve as the core driver for AI entertainment spaces while extending into diverse monetization scenarios—including digital merchandise, brand collaborations, and fan engagement—significantly enhancing both user retention and commercial potential.In addition, Qunabox Group will deepen its diversification layout around the “AI + Consumption Scenarios” strategy. Through strategic acquisitions and ecosystem synergies, the Company will systematically extend its business boundaries and value chain depth to achieve high-quality, scalable growth.From a medium-to-long-term perspective, AI will continue to be the core driving force of industrial transformation, accelerating its penetration into marketing, entertainment, retail, and other scenarios. As a leading company in AI consumption scenarios, Qunabox Group remains at the forefront of AI industry applications through continuous strategic upgrades, technological innovation, and product implementation, building a long-term, sustainable, and high-quality growth flywheel. With the ongoing advancement of its “AI + Consumption Scenarios” strategy, Qunabox Group will unlock new frontiers for innovative growth. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada ACN Newswire

Focus Graphite Announces Board Changes and Upcoming International Trade Mission with Natural Resources Canada

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange ACN Newswire

Shuangdeng Group Proposed Listing on the Main Board of the Hong Kong Stock Exchange

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Global leading storage battery company in data center and telecom industries – Shuangdeng Group Co., Ltd. (stock code: 06960.HK), proposes to list its H Shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).Shuangdeng Group plans to offer 58,557,000 H Shares (subject to the Over-allotment Option), of which 52,701,000 H Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90% of the initial offer shares; the remaining 5,856,000 H Shares will be Hong Kong Offer Shares (subject to reallocation), representing approximately 10% of the initial offer shares. The Offer Price is HK$14.51 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Hong Kong Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund).Shuangdeng Group will open for Hong Kong Public Offering in Hong Kong at 9 a.m., August 18, 2025 (Monday), and close at 12:00 noon, August 21, 2025 (Thursday). Dealings in H shares of Shuangdeng Group on the Main Board of the Hong Kong Stock Exchange is expected to commence on August 26, 2025 (Tuesday). The H shares will be traded in board lot of 500 H shares each. The Company’s stock code will be 06960.HK.China International Capital Corporation Hong Kong Securities Limited, Huatai Financial Holdings (Hong Kong) Limited and CCB International Capital Limited are Joint Sponsors, Sponsor-Overall Coordinators, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Mangers. Sanshui Venture Capital Co., Limited is the cornerstone investor, subscribing for H shares worthing approximately RMB220 million in total.Global leading storage battery company in data center and telecom industriesFounded in 2011 in Taizhou, Jiangsu Province in China, Shuangdeng Group is a leading company in energy storage business for big-data and telecommunication industries. With a deep understanding of the industry and customer demand, Shuangdeng Group has developed industry-leading technologies and multi-pathway products with optimal balance among safety, cost efficiency and performance, which enables it to capture huge growth potential in its industry. According to Frost & Sullivan, in 2024, the Company ranked the first among global telecom base station and data center energy storage battery providers in terms of shipment volume, achieving a market share of 11.1%.With its unwavering commitment to enhance the market recognition of its brand, Shuangdeng Group boast a high-quality global customer base with nearly 30 of the world’s top 100 telecom operators and equipment manufacturers, forging strong relationship with leading telecom operators and telecommunication equipment manufacturers in China, such as China Mobile, China Telecom, China Unicom, and China Tower, as well as prominent international telecommunication giants like Ericsson, Vodafone, Orange, and Telenor. In addition, as of December 31, 2024, Shuangdeng Group served 80% of top 10 Chinese self-owned data center companies and 90% of top 10 Chinese third-party data center companies.R&D capabilities in high safety, cost efficiency and superior performanceShuangdeng Group’s products span diverse application scenarios, including energy storage for telecom base stations, data centers, and the electrical energy storage settings. Shuangdeng Group continuously expand its technology portfolio to encompass lithium-ion batteries, lead-acid batteries, sodium-ion batteries, and solid-state batteries, ensuring it can provide the most suitable products for various application scenarios and diverse customer use. Its R&D efforts are focused on addressing the needs and pain points of customers operating telecom base stations and data centers, with a steadfast commitment to ongoing improvements in safety, cost, and performance of products.Shuangdeng Group has established a technical expert committee led by multiple academicians and comprised of over 30 renowned industry experts. This committee collaborates with distinguished experts from leading institutions such as China Electric Power Research Institute, Tsinghua University, Nanjing University, and Huazhong University of Science and Technology. Together, the Company has developed a long-term, stable research and communication mechanism, regularly engaging in academic exchanges to stay abreast of cutting-edge technological advancements. Through active collaboration between industry, academia, and research, Shuangdeng Group continuously optimizes its product manufacturing process and technologies, driving ongoing innovation. As of August 8, 2025, the Company held a total of 353 patents, including 111 invention patents.Data center business accelerates, emerging as a key growth driverWith the penetration and promotion of big data, technologies, energy storage batteries for data centers have become essential products for ensuring data security and energy security. In 2018, Shuangdeng Group keenly identified the market demands of the internet era and began establishing cooperation relationship with large tech companies and data center operators. Since 2018, the Company has successively collaborated with Alibaba, JD.com, Baidu, GDS, and ChinData. In 2022, Shuangdeng Group innovatively developed the first large-scale dual-function energy storage plan incorporating “backup power + power storage and management” for data centers in China, and supplied our products to the Xiong’an Urban Supercomputing Center, contributing its successful achievement of being recognized as national green data center. Up to August 8, 2025, its energy storage products have been used in hundreds of data centers.According to Frost & Sullivan, in 2024, Shuangdeng Group ranked first among Chinese companies in terms of shipment volumes in the global data center energy storage market and its market share in the global data center market reached 16.1%. Revenues from sales of batteries used in data centers increased by 120% YoY from RMB397.0 million in the five months ended May 31, 2024 to RMB872.9 million in the five months ended May 31. This expansion boosted its contribution to total revenue from 28.4% to 46.7%, making it the company’s largest revenue source. Driven by the increase in revenues from sales of batteries used in data centers, the Company’s total revenues increased from RMB1,394.2 million in the five months ended May 31, 2024 to RMB1,866.6 million in the five months ended May 31, 2025.An experienced and visionary management teamShuangdeng Group is led by a visionary, stable, and highly experienced management team. The Company’s Chairman, Dr. Yang Rui, brings extensive experience in the energy storage battery industry and a global perspective. He has been honored with multiple accolades, including the 2024 Person of the Year in Energy Storage Battery Industry, and Jiangsu Province Excellent Entrepreneur. His forward-thinking strategic decisions have driven the Company’s continuous innovation and growth. Its executive Director and deputy general manager, Dr. Yang Baofeng, is a senior engineer who has received distinguished honors, such as ‘‘Jiangsu Province Technology Entrepreneur’’ and ‘‘Innovation and Entrepreneurship Star.’’ He also serves as Vice Chairman of the China Battery Industry Association and the China Chemical and Physical Power Industry Association. Its senior management team possesses deep expertise in energy storage battery technology and business management. All senior team members have been with us for many years, ensuring effective management collaboration and a unified long-term business strategy.Dr. Yang Rui, Chairman of the Board, Executive Director and Chief Executive Officer of Shuangdeng Group said, “As a global leading storage battery company in data center and telecom industries, we always adhere to our customer-centric approach and devote ourselves to delivering the most suitable and premium batteries to our customers across various industries, including telecom operators and tech companies. As artificial intelligence technology ushers in a new era of widespread adoption, the surging demand for computing power will drive unprecedented growth in energy needs. In response to the expanding demand for computing power and the increasing energy consumption of data centers, we will maintain our innovative drive to seize growth opportunities in the data center sector and cultivate our second growth pillar. Meanwhile, we will continue to deepen our presence and penetration in existing markets while expanding our global presence, further strengthening our position as a globally leading brand.”Use of ProceedsShuangdeng Group estimates that it will receive net proceeds from the Global Offering of approximately HK$756.3 million, assuming the Over-Allotment Option is not exercised, after deducting the underwriting fees and commissions (assuming the full payment of the discretionary incentive fee) and estimated expenses payable by the Company. Approximately 40.0%, or approximately HK$302.6 million, will be used for the construction of a lithium-ion batteries production facility in Southeast Asia. Approximately 35.0% or approximately HK$264.7 million, is intended to be used to fund the establishment of a research and development center. Approximately 15.0%, or HK$113.4 million, is intended to be used to strengthen its overseas sales and marketing so that the Company can enhance its global presence, better serve its overseas customers and boost its international sales. And approximately 10%, or HK$75.6 million, will be used to provide funding for working capital and other general corporate purposes.For further information, please contact:Porda Havas International Finance Communications GroupMs. Kelly Fung+852 3150 6763kelly.fung@h-advisors.globalMs. May Yang+86 21 3397 8725may.yang@h-advisors.global Copyright 2025 ACN Newswire via SeaPRwire.com.
More
CENTRESTAGE 10th anniversary set to dazzle in September ACN Newswire

CENTRESTAGE 10th anniversary set to dazzle in September

- Some 260 brands from 24 countries and regions set to participate, a new high for the event, with the UK debuting as Partner Country to present works by leading British designers- Internationally acclaimed couturier Guo Pei will stage her first solo couture show in Hong Kong, unveiling 30 meticulously crafted pieces under the theme “Gilternity: An Everlasting Radiance”- Aligning with market trends, the fair will introduce a new Accessories Zone and will once again feature the Circular Fashion Zone to promote the development of sustainable fashion- The Fashion Hong Kong Runway Show will celebrate the creative journey of local brands; around 30 fashion shows will be staged during the fair – the highest number in the event’s historyHONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC) and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Government of the Hong Kong Special Administrative Region (HKSAR), CENTRESTAGE – the annual gala event for the Asian fashion industry – takes place from 3 to 6 September 2025 at the Hong Kong Convention and Exhibition Centre (HKCEC). Unveiling a grand celebration of style for its 10th anniversary edition, this year’s CENTRESTAGE sees a record participation of some 260 brands from 24 countries and regions. The programme features more than 40 events, including around 30 fashion shows and parades – another record for the event. The four-day showcase is open to industry professionals and the public free of charge, welcoming visitors from Hong Kong, Mainland China and overseas to experience the charm and creativity of Asia’s fashion capital.Sophia Chong, Deputy Executive Director of the HKTDC, said: “Over the past decade, CENTRESTAGE has become the perfect meeting point for fashion brands and designers from across the globe, and Asia in particular, to showcase their latest creations. As the event celebrates its 10th anniversary, we are truly privileged to welcome internationally acclaimed couturier Guo Pei to present a collection at CENTRESTAGE ELITES, marking her first solo couture show in Hong Kong. As the flagship fashion event for Asia, CENTRESTAGE not only celebrates virtuosity in design and craftsmanship, but also propels both local and international brands into the broader Asian market, supporting the vigorous development of the local fashion industry and reinforcing Hong Kong’s status as a global fashion hub and world-class East-meets-West centre for cultural exchange.”This year’s CENTRESTAGE welcomes fashion brands from across the globe, including pavilions from the United Kingdom, Czech Republic, Japan and Thailand. The UK is participating for the first time as the "Partner Country" of CENTRESTAGE, showcasing unique creations from various British designers. Globally acclaimed fashion maestro Jimmy Choo will not only attend CENTRESTAGE in person but also spotlight his visionary initiative – the Jimmy Choo Academy – showcasing works by emerging designers nurtured by the Academy. The Czechia pavilion will present personalised fashion labels that incorporate art-glass design; the Japan pavilion will spotlight emerging designers and brands, showcasing the creative force of Japan’s new generation; and the Thailand pavilion returns on an unprecedented scale, leading more than 40 brands to the show and expressing the rich diversity of Southeast Asian style. Brands from South Korea, Singapore and other countries will also exhibit their collections at the fair.CENTRESTAGE ELITES sees Guo Pei’s first solo couture show in Hong KongThe prestigious opening event, CENTRESTAGE ELITES, takes place on 1 September at M+ in the West Kowloon Cultural District, with internationally acclaimed couturier Guo Pei presenting her first solo couture show in Hong Kong. Guo Pei was the first Chinese designer invited to join the Fédération de la Haute Couture et de la Mode (FHCM) while also consecutively presenting 10 showcase collections in Paris. She previously participated in HKTDC Hong Kong Fashion Week for Fall/Winter in 2010, closing the Hong Kong Fashion Extravaganza with a spectacular finale.For CENTRESTAGE ELITES, Guo will present 30 one-of-a-kind couture creations under the theme "Gilternity: An Everlasting Radiance", drawing inspiration from the dazzling, fleeting moment of flowing molten gold. Fusing traditional craftsmanship with modern art, the collection epitomises her unparalleled artistry and technical mastery. In a gesture that honours both tradition and innovation, Guo has invited students from Hong Kong Polytechnic University (PolyU) to collaborate on the opening piece for the show.This grand occasion will be livestreamed on the CENTRESTAGE website and Instagram, the HKTDC’s YouTube channel, Facebook and official pages, and across multiple platforms including ViuTV Facebook and Yahoo HK. On the second day of the event (4 September), Guo Pei will appear in person for a master sharing session, offering rare in-person insights into her creative journey and design philosophy.Fashion Hong Kong Runway Show celebrates designers’ creative journeyOn the evening of 3 September, the Fashion Hong Kong Runway Show will take the stage under the theme "A Decade in Design: What is Seen' What is Felt'", exploring Hong Kong designers’ creative journeys. Four Hong Kong designer brands – ANGUS TSUI, ARTY:ACTIVE, IP AXIS INDUSTRIALSTUDIO and selfFab. – will showcase their innovative collections, merging visual impact and emotional narrative to spotlight the unique creativity of Hong Kong fashion design.Six thematic zones showcase sustainability and diversityCENTRESTAGE will be staged across six distinctive thematic zones, each offering its own unique appeal. The new Accessories Zone will present an array of fashion jewellery, handbags, footwear and other refined fashion accents, where style and function are seamlessly intertwined. The Athleisure Zone will champion activewear that unites aesthetics with practicality, reflecting the growing prominence of sports-inspired looks. The Craftsmanship Zone will showcase exquisite techniques and artisanal mastery that pay homage to heritage skills, while the Contemporary Zone will unveil forward‑thinking, avant‑garde creations from cutting‑edge designers. The Urban Zone will spotlight youth‑driven trends, including labels such as Petrolhead, helmed by artist Louis Cheung, which fuses motorcycle culture with a streetwear edge. Completing the lineup, the Circular Fashion Zone will advocate the possibilities presented by sustainable style, headlined by the 15th Redress Design Award Final at which the winning eco‑conscious collections will be showcased, promoting the industry’s focus on environmentally friendly design.The four-day fair will present a rich variety of happenings, including student showcases from PolyU’s School of Fashion and Textiles and the Hong Kong Design Institute, as well as an interdisciplinary exhibition from the Fashion Farm Foundation that combines music, art, product design and intangible cultural heritage, featuring traditional crafts such as gold-thread embroidery in bridal gowns and the making of Canton silk. A record-breaking total of 28 fashion shows will be held throughout CENTRESTAGE, featuring brands such as 112 mountainyam, CAMMIE CHAN CHEONGSAM, DorisKath, and KOWLOON CITY BOY that showcase the vibrant energy of the fashion industry.LOCAL POWER 2025, a cross-cultural project curated by Asian New Generation Creativity Design Association, will officially launch during CENTRESTAGE. This initiative will bring together designers from Hong Kong and Korea, presenting a thoughtfully curated exhibition and runway show that will help to foster cultural and creative exchanges between the two places. “THREAD OF CREATIVITY – Fashion Design Competition 2025" and Knitwear Innovation and Design Society Limited (KIDS) featuring the Young Knitwear Designers' Contest 2025 will also be held during the fair period.The HKTDC will continue to invite buyers from around the world to source at CENTRESTAGE, including major multi-brand stores such as WDLT 117 Apparel Inc. from Canada, Zalora from Indonesia, Sugar Srl from Italy and Hankyu Hanshin Department Stores from Japan.Spotlighting new talent at the YDCThe grand finale of CENTRESTAGE 2025 on Saturday, 6 September will be the Hong Kong Young Fashion Designers’ Contest (YDC), dedicated to discovering and nurturing new local talent. This year's competition will continue to promote a spirit of innovation and experimentation, allowing participants to fully showcase their creativity while injecting fresh talent into the industry. Charles Jeffrey, the designer behind the London label Charles Jeffrey LOVERBOY, has been invited as guest judge, joining a panel of other industry professionals to select winners from the 10 finalists vying for four major awards: Champion, Excellence Award, Best Art Direction and My Favourite Collection. Members of the public are invited to participate by casting votes online (https://bit.ly/YDC2025_IG_Vote_Now) for their favourite collection. Designer brands JESSE LEE and gnastiy.com, both former participants in the YDC, will showcase their new season special collections alongside guest performers at this year's YDC finale.CENTRESTAGE will be staged in parallel with the HKTDC Hong Kong Watch & Clock Fair and Salon de TIME, with visitors able to view the latest products from some 400 watch and fashion brands at the same venue. The fairs will also feature the CENTRESTAGE x Watch & Clock Lucky Draw. The brand-new CENTRESTAGE Instagram account (@centrestage_hktdc) is now officially live and will be updated with the latest event information and fashion trends. Everyone is welcome to follow and stay closely connected with all the latest happenings at CENTRESTAGE.Photo download: https://bit.ly/47uYUFOSharing highlights of this year’s CENTRESTAGE at today’s press conference are Sophia Chong, Deputy Executive Director of the HKTDC (second right); Katherine Fang, Chairman of the HKTDC Garment Advisory Committee (second left); Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (first right); and local fashion designer Angus Tsui (first left).The 2025 CENTRESTAGE exhibition will feature some 260 brands from 24 countries and regions – the largest brand lineup in the event’s history.The grand opening event, CENTRESTAGE ELITES, will be held on 1 September at M+ in the West Kowloon Cultural District. Internationally acclaimed couturier Guo Pei will present her first-ever couture show in Hong Kong. Her "Gilternity: An Everlasting Radiance" collection was previewed at today’s press conference.Akoto Agyeman, Director of Trade & Investment, British Consulate-General Hong Kong (left), and artist Marf Yau (right) wear creations from Patrick McDowell, a brand featuring at the UK Pavillion, at the CENTRESTAGE press conference.Local designer Angus Tsui (left) and artist/emcee Thor Lok (right) showcase a fashion piece designed by Angus Tsui.Websites- CENTRESTAGE: https://www.hktdc.com/event/centrestage/en- CENTRESTAGE ELITES: https://www.hktdc.com/event/centrestage/en/centrestage-elites- CENTRESTAGE Instagram: https://www.instagram.com/centrestage_hktdc/?hl=en- Fashion Hong Kong: https://www.fashionhongkong.com.hk/en- Hong Kong Young Fashion Designers' Contest (YDC): www.fashionally.com/enMedia enquiriesBest Crew Public Relations & MarketingDiana Tang Tel: (852) 9199 6723 Email: diana.tang@bestcrewpr.comReni Kwok Tel: (852) 6291 4283 Email: reni.kwok@bestcrewpr.comHKTDC Communication and Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. About Cultural and Creative Industries Development Agency (CCIDA)The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region (HKSAR Government) under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan.CCIDA’s website: www.ccidahk.gov.hkDisclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
The 35th Food Expo and concurrent fairs attract over 500,000 visits ACN Newswire

The 35th Food Expo and concurrent fairs attract over 500,000 visits

- The Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today, bringing together approximately 1,890 exhibitors and welcoming over 500,000 visits.- The per capital spending across the five fairs reached HK$1,630.- 48% of respondents believe that health, green and organic food trends are worth paying attention to. Halal food and beverage label at the expo helps promote the development of halal foods.- The five theme days, along with a series of exciting activities effectively boosted local consumption and created a bustling atmosphere.- The International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM) featured 21 prominent speakers who shared innovative achievements and development trends in the globalisation of Chinese medicine.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Organised by the Hong Kong Trade Development Council (HKTDC), the Food Expo, Beauty & Wellness Expo, and Home Delights Expo successfully concluded today. Food Expo PRO and the Hong Kong International Tea Fair, which opened to both industry professionals and the public for the first time, wrapped up successfully on 16 August. The five exhibitions featured some 1,890 exhibitors and attracted over 500,000 visits. The bustling atmosphere resulted in a per capita spending of HK$1,630, once again demonstrating the appeal of this annual event and the public’s purchasing power. Over at Food Expo PRO and the Hong Kong International Tea Fair, there were some 18,500 buyers from 64 countries and regions. Apart from Hong Kong, buyers came from Mainland China, Japan, Korea, Taiwan, as well as ASEAN countries, including Cambodia, Malaysia, the Philippines, Thailand, and Vietnam, among others, highlighting Hong Kong's significant role as a key food trade hub globally. Additionally, the International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association (MCMIA) together with the HKTDC and ten scientific research institutions, also concluded successfully on 15 August.Sophia Chong, HKTDC Deputy Executive Director, stated: "This year, the event featured five major themes across several exhibitions, complemented by a variety of exciting activities that encouraged people to spend locally. The atmosphere was vibrant, fully reflecting the public's enthusiasm for gourmet food and trendy products. Due to weather conditions on the first day, the opening hours of the public fairs from Friday to Sunday were extended to provide exhibitors with greater opportunities to maximise sales and enhance visitor experiences. The Hong Kong International Tea Fair, which opened to the public over all three days for the first time, attracted significant attention and praise.”Despite challenges from sluggish trade in traditional markets and geopolitical challenges, the HKTDC has consistently focused on driving innovation, helping small and medium-sized enterprises seize global development trends, and creating opportunities through innovative and flexible thinking.Ms Chong added: “At this year's Food Expo and Food Expo PRO, we specifically curated products and services related to halal food, the silver economy, and food technology to meet emerging market demands and capture more business opportunities for exhibitors. We are pleased to see that the five exhibitions successfully generated more business for exhibitors, and the public enjoyed the culinary and shopping experience fully."Per capita spending reached HK$1,630; increased interest in halal foodsDuring the exhibition, the organisers conducted a random sampling survey, interviewing some 1,440 visitors. The per capita spending reached HK$1,630. Over 58% of respondents reported spending HK$1,000 or more at the exhibition, and over 30% indicated that their actual spending exceeded their original budget, demonstrating a strong and thriving consumption atmosphere during the event. The survey results also showed respondents believe that health, green and organic food (48%), and nutritional supplements (36%) trends are worth paying attention to. Among the respondents who are aware that the exhibition has a halal food and beverage label, more than half of the respondents (52%) believe it helps promote the development of halal foods.Vibrant consumption at the exhibition: encouraging sales performanceAs a highly anticipated annual event in the city, the Food Expo is dedicated to highlighting exquisite delicacies and fine wines from around the world. Director of exhibitor Yick Cheong Ho (HK) Limited, Joan Chui, stated that the Flavours of Intangible Cultural Heritage theme day has drawn extra interest and expected revenue of approximately HK$900,000. Some exhibitors are further expanding their business through the Food Expo. Huaying Lei, the chairman of Mayang Blue Phoenix Agricultural Development Co., Ltd from Mainland China stated that the company had signed a RMB60 million contract with a Hong Kong client for agri-products including high-quality edible eggs. Lei believed the Food Expo offers a perfect platform to showcase their wide-ranging products from Hunan Province.The concurrently held Beauty & Wellness Expo offered visitors a diverse range of premium products, with brand Mars, a Taiwan whey protein brand, the brand marketing manager Roy Wong said, “This year, the visitor traffic exceeded our expectations and we expect our on-site sales will increase by 30% to HK$200,000.”The Home Delights Expo showcased a variety of trendy household items and furniture. Andy Tsang, the design director of Renovation Guide Consultant Limited - specialising in interior design and decoration and participating in the expo for the first time - said, “Such a large number of new customers visiting our booth went above and beyond our expectations. We provided quotations to over 20 new clients, and we estimate that sales turnover will be around HK$2-3 million."Trade exhibitions expand business networks; thriving opportunities in halal foodThe 3rd Food Expo PRO and the 35th Food Expo introduced halal food and beverage label last year to help exhibitors expand their market for halal products. This year, more than 120 food suppliers showcased halal products from around the world, a 20% increase compared to last year. Daniel Chan, Director of Hong Kong exhibitor, Koon Chun Hing Kee Soy & Sauce Factory Ltd., said the company had seen many buyers from different countries and regions and discussed cooperations with five Mainland China and local distributors and restaurants and also met a buyer from Indonesia through the Click2Match platform.The new "Coffee" zone also debuted this year, showcasing coffee products, accessories, and machines from various origins. Jin Lu, Operations Director of CSFA Holdings Shanghai Co. Ltd., stated that the company has engaged with nine exhibitors from Mainland China, the U.S., South Korea, and other regions. The company is interested in placing a coffee beans order of approximately 50 metric tons (worth around RMB3 million) from a Yunnan-based supplier, as well as a RMB700,000 order for premium hairtail fish from a Korea exhibitor.The highlight zone, "Food Science and Technology," brought alternative and future food to the attention of professional buyers. My Care Healthcare Limited, a manufacturer of modified soft diet products for the elderly. Founder Francis Ho said they had discussions with nearly 120 buyers on the first day. On the last day of the fair, HKTDC arranged specialised medical industry buyer tours of which there were two potential buyers and the company is in talks with two hospitals to discuss the potential of supplying soft meals to them.The Okinawa Prefectural Government Hong Kong Representative Office organised four Okinawan companies to participate in the Food Expo PRO and successfully connected with buyers from Hong Kong, Mainland China, and international markets. Director Yasutoshi Nohara stated the fair helps them generate around HK$4 million in orders every year. Mr Nohara said the expo has been instrumental in providing them with a great opportunity, particularly to introduce Okinawan products in the Greater Bay Area and expand beyond Hong Kong with items that have not been shown in other markets before, such as soft shell turtle and Motobu beef.Sichuan Sentaiyuan Biotechnology Co., Ltd. has participated in the Food Expo PRO for four consecutive years, promoting healthy products. The company’s CEO, Liu Lei shared, “On the first day of the Expo, we met a long-time Hong Kong client in person for the first time, leading to a successful deal worth over US$5 million. The HKTDC also introduced several potential buyers from Japan, Singapore, and other regions and we expect deals to be finalised soon.” Mr Lei also mentioned that through the hktdc.com Sourcing platform, the company received around 30 inquiries before the expo and arranged on-site meetings with several clients. The “EXHIBITION+” hybrid model has significantly boosted the company’s visibility and secure more business opportunities.The Hong Kong International Tea Fair opened to trade and public visitors on all three days for the first time. Yip Wing-chi, Founder of exhibitor, Lock Cha Tea House, welcomed this arrangement and noted that there was a significant increase in traffic, creating a lively atmosphere. The public participation has effectively boosted business. Mr Yip said this year's sales were three times higher than last year.Hybrid model connecting local and overseas opportunitiesThis year, both Food Expo PRO and the Hong Kong International Tea Fair continued to adopt the EXHIBITION+ hybrid model, enabling global food and tea buyers to engage in business discussions through both physical exhibitions and online platforms. Until 23 August, exhibitors and buyers can still utilise the "Click2Match" smart matching platform for online discussion and to explore business opportunities.Chinese Medicine Conference Gathers Experts and Scholars to Promote Industry ExchangeThe International Conference of the Modernization of Chinese Medicine and Health Products, organised by the Modernized Chinese Medicine International Association in partnership with the HKTDC and ten scientific research institutions, has successfully concluded. The conference unveiled the latest professional information on traditional Chinese medicine and shared innovative achievements and development trends in the globalisation of Chinese medicine. Held concurrently with the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO, and the Hong Kong International Tea Fair, the event covered diverse fields such as food, beauty, health, home products, and Chinese medicine, successfully creating a synergistic effect, providing a broad platform for industry exchange.Photo download: http://bit.ly/4mrgT4SThe Food Expo, Home Delights Expo, and Beauty & Wellness Expo, three public exhibitions organised by the Hong Kong Trade Development Council, along with the Food Expo PRO and the Hong Kong International Tea Fair, have successfully concluded, attracting over 500,000 visits to attend and shopThe Food Expo PRO featured multiple pavilions showcasing unique culinary delights from different countries and regions, with exhibitors displaying halal food and beverage label gaining increasing attentionThe Federation of Hong Kong Industries and the Incorporated Trustees of the Islamic Community Fund of Hong Kong launched the “Hong Kong Q-Mark Halal Scheme” at the Food Expo PRO, announcing their joint efforts to promote halal certification and its development, fostering the sustainable development of halal products and culture in Hong KongAt the Food Expo PRO, the HKTDC signed a Memorandum of Understanding with The Bank of Saga Ltd., to promote businesses in Saga, Fukuoka, and Nagasaki to further their development in Hong Kong and beyond, revitalising both the local economy and prosperity of the regionThe Hong Kong International Tea Fair opened to the public for the first time over its three-day exhibition period, drawing many visitors to explore a variety of tea beveragesThe five major theme days ran throughout the exhibition period, with the opening day (14 August) featuring "Shall We Tea'”, focusing on demonstrations of Northern and Southern dim sum and creative dim sum making, tea therapy workshops and other exciting activitiesOn 15 August, “Flavours of Intangible Cultural Heritage” featured hands-on experiences in making traditional Hakka “hand-pulled” noodles, as well as introductions to intangible cultural heritage steamer and bamboo craftmanship culture, along with steamer craft demonstrationsOn 17 August, “Body, Mind & Soul” responds to the business opportunities brought by the silver economy, with exhibitors launching a variety of products and services tailored for seniorsThe Beauty & Wellness Expo has introduced a new Polish pavilion this year, showcasing high-quality products such as caviar essence cream, pure natural essential oils, hair growth serums, and other products. The newly-established "Scentsation" zone focuses on perfumes and aromatherapy, featuring over 20 participating brandsThe Home Delights Expo's "Avenue of Delights" brand zone included more than 35 exhibitors, showcasing various lifestyle brandsThroughout the exhibitions, a series of highly popular and exciting events were held, including "Star Chef Cooking Demonstrations”, "Smart Bidding", and lucky drawsThe International Conference of the Modernization of Chinese Medicine and Health Products presented the latest professional information on Chinese medicine. The conference, themed "The Latest Research Progress in the Prevention and Treatment of Tumours, Inflammation and Cardiovascular and Cerebrovascular Diseases with Traditional Medicine", featured 21 prominent speakers, including experts from Hong Kong, mainland China, and overseas, sharing innovative achievements and development trends in the globalization of Chinese medicineTo learn more about the opinions of exhibitors and buyers, please visit:HKTDC Food Expo PROfoodexpopro.hktdc.comHong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine and Health Products (ICMCM)icmcm.hktdc.com Media EnquiriesOgilvy Public Relations:Rex CheukTel:(852) 5618 9908email: rex.cheuk@ogilvy.comLeanne PokTel:(852) 9379 9694 email: leanne.pok@ogilvy.comDaisy LeungTel:(852) 9275 7704email: daisy.leung@ogilvy.comHKTDC’s Communications and Public Affairs Department:Stanley SoTel:(852) 2584 4049email: stanley.hp.so@hktdc.orgSerena CheungTel:(852) 2584 4272email: serena.hm.cheung@hktdc.orgClayton LauwTel:(852) 2584 4472email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.
More
中國生物製藥(1177.HK)公佈2025中期業績 ACN Newswire

中國生物製藥(1177.HK)公佈2025中期業績

重點成果- 期內,集團共有2個創新產品獲中國國家藥品監督管理局(「NMPA」)批准上市,分別為普坦寧(美洛昔康注射液(II))和安啟新(注射用重組人凝血因子VIIa N01)。- 2025年上半年,集團創新產品收入達到人民幣78億元,同比增長27.2%。除創新產品外,集團還有5個仿製藥獲NMPA批准上市,整體仿製藥收入在2025年上半年保持正增長。- 截至2025年6月30日,集團共有37個腫瘤領域、7個肝病╱代謝領域、13個呼吸系統領域、和6個外科╱鎮痛領域的創新候選藥物處於臨床申請及以上開發階段。其中,2個腫瘤領域、1個外科╱鎮痛領域產品處在上市申請階段;11個腫瘤領域、1個肝病╱代謝領域、3個呼吸系統領域、1個外科╱鎮痛領域的創新候選藥物處於臨床III期;另有13個腫瘤領域、6個肝病╱代謝領域、12個呼吸系統領域、6個外科╱鎮痛領域的生物類似藥或仿製藥候選藥物處於臨床申請及以上開發階段。- 福可維(鹽酸安羅替尼膠囊)是一種新型小分子多靶點酪氨酸激酶抑制劑,目前已獲批9個適應症,另有3個適應症處於上市申請階段。此外,安羅替尼還有多項新適應症處於III期臨床研究階段,包括一線非鱗狀非小細胞肺癌、一線胰腺癌等,預計將在未來兩年逐步遞交上市申請。- 2023-2024年,集團共有5款腫瘤領域的國家1類創新藥獲批上市,分別為:億立舒(艾貝格司亭α注射液)、安得衛(貝莫蘇拜單抗注射液)、安柏尼(富馬酸安奈克替尼膠囊)、安洛晴(枸櫞酸依奉阿克膠囊)和安方甯(格索雷塞片);以及4款腫瘤領域的生物類似藥獲批上市,分別為:安倍斯(貝伐珠單抗注射液)、得利妥(利妥昔單抗注射液)、賽妥(注射用曲妥珠單抗)和帕樂坦(帕妥珠單抗注射液)。該等產品在2025年上半年快速放量,成為集團收入增長的重要貢獻品種。- 拉尼蘭諾(泛PPAR激動劑)是一種口服小分子藥物,用於治療代謝功能障礙相關脂肪性肝炎(MASH),目前正在全球開展III期臨床試驗,已完成全部受試者入組。2023年7月,拉尼蘭諾被藥品評審中心「CDE」納入突破性治療藥物程序。拉尼蘭諾是中國第一個進入臨床III期的MASH口服藥物,有望填補中國市場空白。- 天晴速暢(吸入用布地奈德混懸液)是中國首款獲批上市的布地奈德霧化劑型仿製藥,打破了國內市場長期被原研壟斷的局面,為國內氣道慢性炎症患者帶來了兼具有效性、安全性與經濟性的高端製劑產品。該產品已被納入集採範圍,集團及時採取了一系列主動管理措施,包括管道下沉、拓展市場覆蓋和集採外市場的二次開發。- 澤普思╱得百安(氟比洛芬凝膠貼膏)是中國首個獲批上市的國產凝膠貼膏,連續多年蟬聯外用鎮痛市場份額第一位。集團聚焦高潛力地區開發,深入拓展市場覆蓋,並逐步擴大產能以滿足市場的旺盛需求,推動澤普思/得百安銷售額持續快速增長。集團開發的第二代氟比洛芬貼劑預計將在一年內獲批上市。通過劑型升級,二代產品可顯著提高藥物透皮吸收度,增強貼膏粘附性,從而提升患者的依從性。香港,2025年8月18日 - (亞太商訊 via SeaPRwire.com) - 中國領先的創新研發驅動型醫藥集團-中國生物製藥有限公司(「中國生物製藥」或「公司」,連同附屬公司統稱「集團」)(股票編號:1177)公佈截至2025年6月30日止6個月(「期內」)之未經審核財務業績。回顧期內,集團收入同比增長10.7%至約175.7億元(人民幣,下同)。來自持續經營業務之歸屬於母公司持有者應佔盈利財務報表所示約33.9億元,同比增長約140.2%,基於歸屬於母公司持有者應佔盈利計算之每股盈利約18.82分。歸屬於母公司持有者盈利同比顯著增長主要受惠於本期間收入明顯增長及股息收益和投資公允價值變動收益明顯增長。歸屬於母公司持有者之基本溢利(非香港財務報告準則指標)約30.9億元,同比增長約101.1%。集團流動資金保持充裕,期內有計入流動資產之現金及銀行結餘約111億元、計入非流動資產之銀行存款約101億元,理財管理產品總額約92.9億元,資金儲備合共約304.9億元。董事會建議派發中期股息每股5港仙(2024上半年:3港仙)。銷售:研發創新動能強勁,多領域銷售成果持續放量集團一直以來重視研發,持續加大投入以提升研發質效,研發實力顯著增強,驅動銷售收入持續增長,成果豐碩。期內,抗腫瘤用藥之收入同比增加24.9%,達約66.9億元,佔集團收入約38.1%。外科/鎮痛用藥之收入同比增加20.2%,達約31.1億元,佔集團收入約17.7%。腫瘤領域,集團全面佈局非小細胞肺癌領域,覆蓋多種分型的全線治療,EGFR/cMet雙抗TQB2922即將啟動二線非小細胞肺癌III期臨床,EGFR/cMet雙抗ADC TQB6411 I期臨床正在入組,兩款產品進度均位於中國前列;深度佈局乳腺癌三大亞型, CDK2/4/6抑制劑庫莫西利膠囊有望成為HR+/HER2-乳腺癌的BIC療法,HER2雙抗ADC TQB2102較DS-8201潛在安全性優效,多個適應症正在同步拓展,其中三項乳腺癌III期快速推進;系統佈局消化道領域結直腸癌、胃癌、胰腺癌、肝癌等核心癌腫,LM-108(CCR8單抗)、TQB2868(PD-1/TGF-β雙功能融合蛋白)研發進度全球最快,且目前臨床數據展示出了極大潛力。於外科╱鎮痛領域,集團持續聚焦高潛力地區開發,深入拓展市場覆蓋,並逐步擴大產能以滿足市場的旺盛需求。期內,集團推動澤普思銷售額持續快速增長,而開發的第二代氟比洛芬貼劑預計將在一年內獲批上市。同時,2025年5月獲批的普坦寧憑藉長效鎮痛、安全性優異等優勢,有望成為該領域新的增長動力。研發:全力以赴推動創新產品開發,加大研發的資金投入於報告期內,集團共有2個創新產品獲NMPA批准上市,分別為普坦寧(美洛昔康注射液(II))和安啟新(注射用重組人凝血因數VIIa N01)。2025年上半年,集團創新產品收入達到人民幣78億元,同比增長27.2%。除創新產品外,集團還有5個仿製藥獲NMPA批准上市,整體仿製藥收入在2025年上半年保持正增長。一直以來,集團十分重視研發,不斷提升研發水平和速度,並視其為可持續發展的基礎,加大研發的資金投入。截至二零二五年六月三十日止六個月,研究與開發成本約人民幣318,756萬元,佔本集團收入約18.1%,連同已資本化的研發總開支出在內,約95.7%已計入損益表中。展望:深化創新與國際化布局,加速構建全球醫藥創新競爭力當前,中國醫藥產業正迎來歷史性發展機遇。在國家創新驅動發展戰略的指引下,我國生物醫藥創新能力顯著提升,創新藥研發已從「跟跑」逐步邁向「並跑」甚至「領跑」階段。中國創新藥不僅在本土市場構建起強勁的增長勢能,更在全球市場逐步嶄露頭角,日益獲得廣泛認可,已成為全球醫藥創新產業中不可替代的重要力量。作為行業領軍企業,集團深耕腫瘤、肝病╱代謝、呼吸系統及外科╱鎮痛四大核心治療領域,專注創新,服務病患,目標成為全球領先的製藥企業。集團深耕中國市場,同時將戰略視野投向全球市場,以國際化加速創新發展。同時,集團大力推進全球戰略合作佈局,通過商務拓展(BD)、戰略收購等多元合作路徑,快速充實創新管線儲備,強化核心技術平台。2025年7月,集團宣布全資收購禮新醫藥。禮新醫藥擁有全球領先的抗體發現和ADC技術平台,包括腫瘤微環境特异性抗體開發平台 (LM-TME™)、針對難成藥靶點的抗體開發平台(LM-Abs™),新一代抗體偶聯藥物平台(LM-ADC™)、以及免疫細胞銜接器平台(LM-TCE™)。此次收購將進一步增强集團的創新研發能力,加速集團的創新業務增長。此外,禮新醫藥卓越高效的研發團隊將加入集團,進一步强化集團的創新研發人才儲備,為持續產出高水平創新成果提供保障,助力創新生態的長遠發展。未來,本集團將繼續聚焦創新,提升四大治療領域的研發效率與質量,加快國際化步伐,力爭實現業務快速發展與業績穩步提升。有關中國生物製藥有限公司(股票編號:1177)中國生物製藥,連同其附屬公司,是中國領先的創新研究和研發驅動型醫藥集團,業務覆蓋醫藥研發平臺、智慧化生產和強大銷售體系全產業鏈。產品包括多種生物藥和化學藥,在腫瘤、肝病/代謝、呼吸系統、外科/鎮痛四大治療領域處於優勢地位。公司於2000年在香港聯交所上市,2013年入選MSCI全球標準指數之中國指數成分股;2018年入選恒生指數成分股;2020年入選恒生滬深港通生物科技50指數成分股、恒生中國(香港上市)25指數。中國生物製藥連續七年榮登美國權威雜誌《製藥經理人》發佈的「全球製藥企業TOP50」,連續三年獲評《福布斯》(亞洲) 「亞太最佳公司50強」。有關中國生物製藥的進一步資料,請瀏覽: www.sinobiopharm.com Copyright 2025 亞太商訊 via SeaPRwire.com.
More
雙登股份宣佈於香港聯交所主板上市計劃 ACN Newswire

雙登股份宣佈於香港聯交所主板上市計劃

香港,2025年8月18日 - (亞太商訊 via SeaPRwire.com) - 全球領先的數據中心及通信基站儲能電池公司--雙登集團股份有限公司(股份代號:06960.HK)計劃將於香港聯合交易所有限公司(「香港聯交所」)主板上市H股股份。雙登股份將發售58,557,000股H股(視乎超額配股權行使與否而定),其中52,701,000股H股 (可予重新分配及視乎超額配股權行使與否而定)將作國際發售,合共佔初步發售股份總數的90%;餘下5,856,000股H股 (可予重新分配)將於香港作公開發售,合共佔初步發售股份總數的10%,每股價格爲14.51港元,另加1.0%經紀佣金、0.0027% 證監會交易徵費、0.00565%香港聯交所交易費及0.00015%會財局交易徵費(須於申請時以港元繳足,並可予退還)。雙登股份將於2025年8月18日(星期一)上午9時開始於香港公開發售,並於2025年8月21日(星期四)中午12時截止。雙登股份的股票預計將於2025年8月26日(星期二)於香港聯交所主板開始進行買賣,股份將按每手買賣單位500股H股買賣,股票代號爲06960.HK。中國國際金融香港證券有限公司、華泰金融控股(香港)有限公司、建銀國際金融有限公司為本次發行之聯席保薦人、保薦人兼整體協調人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人。基石投資者為三水創業投資有限公司,認購總額約合220百萬人民幣。全球領先的數據中心及通信基站儲能電池公司雙登股份於2011年於中國江蘇省泰州成立,是大數據及通信領域能源存儲業務的領先公司。憑藉對行業及客戶需求的深入理解,雙登股份開發行業領先的技術及安全性、成本效益及性能之間最佳平衡的多途徑產品,使公司能夠緊抓行業的巨大增長潛力。根據弗若斯特沙利文的數據,於2024年,雙登股份在全球通信及數據中心儲能電池供應商中出貨量排名第一,市佔率達11.1%。憑藉對提升品牌市場認可度的堅定承諾,雙登股份擁有高品質的全球客戶群,覆蓋接近30家全球百大通信運營商及設備製造商,與中國移動、中國電信、中國聯通、中國鐵塔等中國領先的通信運營商和通信設備製造商,如愛立信、沃達豐、法國電信、挪威電信等國際知名通信領域知名企業均建立了堅實的合作關係。此外,截至2024年12月31日,公司服務了中國十大自有數據中心企業的80%,以及中國十大第三方數據中心企業的 90%。強大的研發能力,打造安全性高、符合成本效益及性能優越的產品雙登股份的產品覆蓋了通信基站儲能、數據中心儲能、電力儲能等多元化應用場景。公司持續拓展鋰電池、鉛酸電池、鈉離子電池、固態電池等技術組合,確保能夠為各種應用情境和不同客戶匹配最合適的產品。雙登股份的研發聚焦於解決通信基站及數據中心的需求和痛點,並堅定致力於在安全、成本及性能方面不斷精進。雙登股份成立了以多名院士為首的30多位行業知名專家組成的技術專家委員會,與來自中國電力科研究學院、清華大學、南京大學、華中科技大學等領先機構的傑出專家合作。公司共同建立了長期穩定的科研合作機制,定期開展學術交流,及時掌握前沿的技術發展動向。通過積極開展產學研合作,雙登股份不斷優化產品工藝和技術,促進產品技術持續創新。截至2025年8月8日,雙登股份共擁有353項專利,其中發明專利111項。數據中心業務加速 成核心增長引擎隨著大數據技術的滲透與推廣,數據中心儲能電池成為保障資料安全及能源安全的必要產品。於2018年,雙登股份敏銳捕捉互聯網時代市場需求,並開始與大型科技企業、數據中心運營商等客戶建立合作關係。自2018年以來,公司陸續與阿里巴巴、京東、百度、萬國及秦淮數據等達成合作。於2022年,公司創新性在中國打造的首例規模化數據中心「備電+儲能」複合儲能項目,成功向雄安城市超算中心供應產品,助力其成功獲認可為國家綠色數據中心。截至2025年8月8日,雙登股份的數據儲能產品已累計應用於數百家數據中心。根據弗若斯特沙利文,於2024年,雙登股份在全球數據中心儲能市場的出貨量排名中國企業第一,在全球數據中心市場份額達到16.1%。截至2025年5月31日止五個月,雙登股份来自數據中心業務的收入由截至2024年5月31日止五個月的人民幣397.0百萬元增加近120%至人民幣872.9百萬元,收入占比從28.4%升至46.7%,成為公司第一大收入來源。得益于數據中心銷售收入增加,公司的总收入由截至2024年5月31日止五個月的人民幣1,394.2百萬元增加至截至2025年5月31日止五個月的人民幣1,866.6百萬元。經驗豐富以及前瞻遠矚的管理團隊雙登股份由一支高瞻遠矚、穩定並擁有豐富行業經驗的管理團隊領導。公司的董事長楊銳博士擁有豐富的儲能電池行業經驗和國際視野。彼獲得2024年儲能電池行業年度人物及江蘇省優秀企業家等多項榮譽。彼以極具前瞻性的戰略決策帶領公司持續創新和發展。雙登股份的執行董事兼副總裁楊寶峰博士擁有高級工程師職稱,榮獲江蘇省科技企業家及「雙創之星篇先進典型」等榮譽,擔任中國電池工業協會副理事長、中國化學與物理電源行業協會副理事長。高級管理團隊具備精深的儲能技術和經營管理的專業知識。所有高級管理團隊成員均已在公司任職多年,使得公司的管理協作更為行之有效,長期業務戰略更為統一。雙登集團股份有限公司董事會主席、執行董事及行政總裁楊銳博士表示:「作為全球領先的數據中心及通信基站儲能電池公司,我們始終堅持以客戶為中心,致力於為包括通信運營商及科技企業等客戶提供最適合、最優質的電池產品。隨著人工智能技術邁入普及應用的新紀元,其算力需求蓬勃增長將帶來電力能源需求的爆發式增長。面對算力需求持續擴大、數據中心能耗增長而帶來的需求,我們將保持創新,把握數據中心領域的發展機遇,打造我們的第二增長極。此外,我們还將繼續深化現有市場的佈局和滲透,同時擴大全球化佈局力度,進一步鞏固全球領先品牌地位。」所得款項用途假設超額配股權未獲行使,經扣除包銷費用及佣金(假設悉數支付酌情獎勵費用)及應付估計開支後,公司將自全球發售獲得所得款項淨額約756.3百萬港元,其中淨額約40%或約302.6百萬港元,預計將用作於東南亞興建一個鋰離子電池生產設施;約35%或約264.7百萬港元,擬用於建立研發中心;約15%或113.4百萬港元,擬用作加強海外銷售及營銷,以便能夠增強公司的全球影響力、更好地服務海外客戶並促進國際銷售;餘下約10%或75.6百萬港元,擬用作營運資金及其他一般企業用途。如有垂詢,請聯絡︰博達浩華國際財經傳訊集團馮嘉莉+852 3150 6763kelly.fung@h-advisors.global楊冬梅+86 15021840493may.yang@h-advisors.global Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Shoucheng Portfolio Wins 37 Medals at Humanoid Robot Games ACN Newswire

Shoucheng Portfolio Wins 37 Medals at Humanoid Robot Games

HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - On August 17, 2025, the inaugural World Humanoid Robot Games—an international event centered on humanoid robots—concluded successfully at the National Speed Skating Oval in Beijing, also known as the “Ice Ribbon.”Co-hosted by the Beijing Municipal Government, China Media Group, the World Robot Cooperation Organization, and the Asia-Pacific RoboCup Council, the Games gathered 280 teams and over 500 robots from around the globe to compete across 26 disciplines, showcasing the full industrial chain from technological breakthroughs to real-world applications in embodied intelligence.As a key industrial accelerator, Shoucheng Holdings (0697.HK) saw several of its portfolio companies participate in major events, collectively winning 37 medals (12 gold, 14 silver, and 11 bronze), including awards where teams utilized robots built by Shoucheng’s portfolio firms. Simultaneously, Shoucheng launched the "Shoucheng Robot Tech Experience Store" adjacent to the venue, which became one of the most visited tech exhibits of the event.Highlights from Portfolio Companies:Unitree Robotics captured 4 gold medals and achieved a top speed of 4.78 m/s; G1-based teams earned an additional 1 gold, 1 silver, and 1 bronze;Beijing Humanoid Robot Innovation Center won 2 gold, 6 silver, and 2 bronze, representing the most advanced “fully autonomous execution” capabilities;Noetix Robotics earned 2 gold, 1 silver, and 1 bronze in gymnastics, long jump, and dance events, becoming a standout in “Tech × Art” integration;Galbot (by Galbot Technologies) secured the autonomous sorting championship and supported university teams that swept the podium;Galaxea-AI served as exclusive hardware provider in scene-based competitions and enabled a third-place finish by Beihang University;Booster Robotics powered all 3V3 and 5V5 football events, providing robot hardware and technical support, and was deemed the “backstage champion.”Robot Tech Experience Store: Bringing Innovation to the EverydayDuring the event, Shoucheng launched a pop-up “Robot Tech Experience Store,” featuring over 200 smart products across home, education, entertainment, healthcare, and wearables. The official store will open during China’s National Day Golden Week in October 2025 at Fusion Stone Plaza, Beijing, with nationwide expansion plans into airports, campuses, and commercial hubs.As Shoucheng’s Executive Director and Co-President Ye Qian stated: “Through interactive and relatable scenarios, we want the public to feel that robots are no longer distant technologies—they’re becoming part of daily life.”From Lab to Market: Accelerating the New Productive ForceWith a dual strategy of equity investment and asset operations, Shoucheng Holdings will continue to drive commercialization of humanoid and embodied robots in education, manufacturing, healthcare, and smart city operations, unlocking the full potential of the next-generation productivity paradigm.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.
More
勇奪12金14銀11銅 首程控股多家被投企業閃耀世界人形機器人運動會 ACN Newswire

勇奪12金14銀11銅 首程控股多家被投企業閃耀世界人形機器人運動會

香港,2025年8月18日 - (亞太商訊 via SeaPRwire.com) - 2025年8月17日,全球首個以人形機器人為核心參賽主體的大型綜合性賽事--世界人形機器人運動會,於北京國家速滑館「冰絲帶」圓滿落幕。本屆運動會由北京市人民政府、中央廣播電視總台、世界機器人合作組織、亞太機器人世界盃國際理事會等單位聯合主辦,共匯聚全球280支戰隊、超過500台機器人同場競技,全面展示具身智能機器人從技術突破到場景落地的完整產業鏈條。作為深度產業推動者,首程控股(0697.HK)所投企業整體表現亮眼,共計斬獲37枚獎牌(含金牌12枚、銀牌14枚、銅牌11枚),涵蓋各戰隊使用被投企業機器人本體參賽所獲獎項。與此同時,首程控股亦於「冰絲帶」外場設立面向公眾開放的「首程機器人科技體驗店」,成為本屆大會最受歡迎的科技互動展區之一。一、亮點企業集結亮相:宇樹科技:勇奪4金,並創下4.78m/s速度紀錄,G1平台支持隊伍再獲1金1銀1銅;北京人形機器人創新中心:展現「全自主執行」技術優勢,累計摘得2金6銀2銅;松延動力:橫掃自由體操、跳遠及舞蹈賽事,共奪2金1銀1銅,成為「科技×藝術」融合典範;銀河通用:凭藉全自主操控勇奪分揀技能競技冠軍,並協助高校戰隊包攬冠亚軍;星海圖:作為場景賽整機平台提供商,支持多所頂尖高校參賽,並助北京航天航空大學奪得季軍;加速進化:作為足球賽項技術平台提供方,為所有參賽隊提供機器人硬體與技術保障,成為「幕後冠軍」。二、打造機器人應用樣板:首程體驗店引領科技走入生活體驗店共展出超過200款智能產品,涵蓋家庭、教育、娛樂、醫療等多元場景,並將於2025年國慶黃金周正式落戶北京石景山・融石廣場,未來擴展至全國商圈、機場、高校等重點場域,開啟連鎖化推廣計劃。首程控股執委、聯席總裁葉芊表示:「我們希望通過真實場景的互動設計,讓大眾感受到機器人正從技術實驗室走向日常生活。」三、從實驗室走向真實應用,下一代生產力加速落地首程控股將持續依託「股權投資+資產運營」雙輪驅動戰略,攜手產業鏈合作夥伴推動具身智能機器人於教育、製造、醫療、城市運營等核心領域的產業化落地,釋放「下一代生產力」的巨大潛力。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亞太商訊 via SeaPRwire.com.
More
Everest Medicines’ New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access ACN Newswire

Everest Medicines’ New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC).Building on prior approvals in Singapore, Hong Kong SAR, and Macao SAR, as well as NDA acceptance in South Korea, this marks significant progress in the commercialization of VELSIPITY(R) across Asia. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R).As a next-generation selective S1P receptor modulator, once-daily oral etrasimod demonstrates robust efficacy across multiple endpoints, including clinical remission, mucosal healing, endoscopic normalization and histological remission. Its clinical value has been robustly demonstrated in multiple global Phase III studies, including ELEVATE UC 52, ELEVATE UC 12 and ENLIGHT (ES101002) studies.“The NDA acceptance for VELSIPITY(R) in Taiwan, China marks another key progress in our commercialization pathway across Asia. As the number of UC patients in Asia continues to rise, there remains a significant unmet medical need. In China alone, there were approximately 800,000 patients with UC in 2024, and the number is estimated to reach 1 million by 2030. UC patients face the dual challenges of long-term treatment and maintaining quality of life." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “This NDA acceptance underscores the clinical value of VELSIPITY(R). We remain committed to accelerating access to this innovative therapy in Mainland China and other Asian markets, supporting long-term disease management while enhancing patients’ quality of life.”The clinical part submitted to TFDA is mainly based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) and the ENLIGHT study (ES101002). The ELEVATE UC Phase 3 registrational program evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.The ENLIGHT study (ES101002) conducted by Everest, is a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including China Mainland, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately to severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The results demonstrate that treatment with etrasimod 2 mg resulted in a clinically meaningful and statistically significant improvement in the primary and all secondary endpoints. These findings provide strong evidence supporting the use of etrasimod in adult Asian patients with moderately to severely active ulcerative colitis.As Everest’s third commercialized product, VELSIPITY(R) has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. Additionally, Everest has launched a factory construction project at its Jiashan site to support local production of VELSIPITY(R). Copyright 2025 ACN Newswire via SeaPRwire.com.
More
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million ACN Newswire

Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its interim results for the six months ended 30 June 2025.Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG Guoxiong (center), Executive Director and Chief Executive Officer Ms. OU Haijing (left), and Chief Financial Officer Mr. KWAN Chi Fai (right)2025 Interim Results Highlights:- Overall operation was stable, with total revenue of RMB966 million (corresponding period of 2024: RMB1,034 million).- As at 30 June 2025, the overall occupancy rate of the properties was 82.2% (corresponding period of 2024: 84.0%).- The average financing cost was 3.33%, representing a decrease of 83 basis points from the beginning of the year. Excluding exchange loss, financing expenses decreased by 13.5% year-on-year.- Interim distribution of approximately RMB0.0333 per unit, equivalent to approximately HK$0.0366. This represents an annualized distribution yield of 8.42%.Guangzhou International Finance Center (GZIFC):- Operating revenue of the GZIFC complex was RMB486 million, accounting for 50.3% of the REIT’s total revenue.- Its office building introduced a Fortune Global 500 company, the occupancy rate was 82.6%, and the renewal rate was 70%.- GZIFC Shopping Mall had a high occupancy rate of 96.4% during the period.- Four Seasons Hotel Guangzhou achieved a 1.1-percentage-point year-on-year increase in average occupancy rate with record room revenue for the period, while Ascott Serviced Apartments GZIFC recorded a 1.8-percentage-point rise in average occupancy and similarly reached historic highs in revenue.Yuexiu Financial Tower:- Yuexiu Financial Tower recorded operating revenue of approximately RMB165 million, representing 17.1% of the REIT’s total revenue. The occupancy rate was 82.1%.- The tenant structure continued to improve, with new introduction of quality tenants such as a Fortune Global 500 company and a futures company with a market value exceeding RMB10 billion.Proactive Management of Financing Risk and Effective Stabilization of Financing Cost- With regard to the short-term loan of RMB530 million and the 5-year syndicated loan of HK$2.1 billion, both due in the first half of 2025, and other loans which are due within the year, the Manager in the first half of 2025 renewed the short-term loan of RMB530 million, obtained offshore loan of RMB1.7 billion and issued dim sum bonds of RMB1 billion for the refinancing and early repayment of the maturing loans so as to ensure effective monitor on the liquidity risk.- The Manager introduced a total of RMB3.23 billion in loans in the first half of 2025 to refinance offshore HKD floating rate loans, taking advantage of the relatively low-cost of RMB financing to proactively adjust the financing structure, thereby minimizing the impact of the interest rate market. At the end of the first half of 2025, the financing interest rate exposure of Yuexiu REIT was approximately 14%, narrowing by 12 percentage points from 26% at the beginning of the year; the average financing cost was 3.33%, representing a decrease of 83 basis points from 4.16% at the beginning of the year; the average interest payment rate for the first half of the year was 3.92%, representing a year-on-year decrease of 64 basis points. Excluding the exchange loss, the finance expenses amounted to approximately RMB402 million, representing a year-on-year decrease of 13.5%.- As at the end of June 2025, Yuexiu REIT had RMB financing of approximately RMB14,795 million, accounting for 72% of total financing (corresponding period of 2024: RMB financing of approximately RMB8,404 million, accounting for 41% of total financing).Mr. JIANG Guoxiong, Chairman and Non-Executive Director of Yuexiu REIT, said, "In the first half of 2025, against the backdrop of global trade volatility and slowing economic growth, China's GDP achieved steady growth of 5.3%, yet corporate expansion remained cautious and slow; retail consumption was weak, and average daily rate of hotel and apartment was under pressure. In order to effectively deal with the headwinds in the industry, we took strategic actions to secure market share by renewing leases in advance, investing in asset appreciation projects to enhance product competitiveness, and effectively stabilizing the fundamentals of operations, which effectively supported the revenue of Yuexiu REIT for the Interim Period. Meanwhile, lower financing cost is beneficial to the distributions.”Guangzhou International Finance Center (GZIFC)GZIFC achieved positive growth in both customer flow and conversion rates through product enhancement and operational optimisation, with a newly contracted area of 13,133 sq.m.. The newly launched 4,235 sq.m. of furnished units recorded an absorption cycle of only about 19 days, with an absorption rate close to 90%. Quality tenants introduced include a Fortune Global 500 company, a leading global shipping company, and a renowned Internet-based culture, sports and entertainment company, taking up more than 2,200 sq.m. in aggregate. In addition, the project recorded a renewed leasing area of 9,099 sq.m. and a renewal rate of 70%, retaining quality tenants including two Fortune Global 500 companies and a foreign consulate. GZIFC was selected as one of the Top 30 companies in the “Performance Index - 2025 Commercial Property Operation Performance” by Guandian.GZIFC Shopping Mall actively created digitalized consumption scenarios, advanced the pilot implementation of the local lifestyle platform “YueXiu Club”, which now covers 12 merchants, while attracting customers through multiple channels such as Dianping and UnionPay QuickPass platforms. Newly contracted area and renewed leasing area totaled 5,734 sq.m., with a renewal rate of 97% and the occupancy rate of 96.4%. During the period, it was announced that China Duty Free Group (CDFG) will set up a store in GZIFC Shopping Mall, which will be the first and currently the only downtown duty-free store in Guangzhou and is expected to open in the third quarter.Room revenue of Four Seasons Hotel Guangzhou and revunue of Ascott Serviced Apartments GZIFC reached a record high for the period, respectively. During the period, the average occupancy rate of Four Seasons Hotel Guangzhou reached 80.1%, representing a year-on-year increase of 1.1 percentage points. The average room rate was RMB2,201, similar to the same period last year. The revenue per available room (RevPAR) was RMB1,762, representing a year-on-year increase of 0.7%. The RevPAR competitive index was 111.7, maintaining a leading market position among luxury hotel competitors. The average occupancy rate of Ascott Serviced Apartments GZIFC reached 92.3%, representing a year-on-year increase of 1.8 percentage point and 9.7 percentage points higher than that of serviced apartment competitors. The average room rate was RMB1,128, similar to the same period last year. The RevPAR was RMB1,041, representing a year-on-year growth of 1.5%. The RevPAR competitive index reached 120.0.Yuexiu Financial TowerDuring the period, Yuexiu Financial Tower recorded a newly contracted area of 7,448 sq.m., including a total of 1,500 sq.m. further took up by seven existing tenants looking for expanded area. 7,089 sq.m. of furnished units were launched, with with an absorption cycle of approximately 38 days and an absorption rate of more than 65%. Quality tenants newly introduced include a Fortune Global 500 company and a futures company with a market value of over RMB10 billion. As certain tenants relocated to their own properties, the project recorded a renewed leasing area of 10,303 sq.m. and a renewal rate of 42%, retaining quality tenants with large leasing areas, including Deloitte, one of the Big Four international accounting firms, and a leading integrated asset management company in China.White Horse BuildingDuring the period, White Horse Building introduced supply chain resources from the Pearl River Delta and recorded a newly contracted area of 3,273 sq.m., with full occupancy on the 1st floor. In the first half of 2025, it welcomed a total of 165 procurement delegations, along with nearly 5,000 purchaser visits, including 23 foreign delegations from France, Vietnam and other countries, and facilitated procurement deals worth RMB140 million. By taking advantage of exhibitions such as the Greater Bay Area International Women’s Wear Expo and the Canton Fair, White Horse Building facilitated tenant transactions. It also successfully launched the cross-border e-commerce platform “White Horse Global E-Channel” and set up a series of courses titled “White Horse Business School Marketing Empowerment Camp” to activate new momentum for tenants’ digital operations.Fortune PlazaDuring the period, the project recorded a newly contracted area of 2,354 sq.m., and introduced quality tenants including several healthcare and elderly care subsidiaries of a Fortune Global 500 integrated financial group. The project recorded a renewed leasing area of 2,924 sq.m. and a renewal rate of 76%, retaining quality tenants including a Fortune Global 500 company, and flexibly adjusted units to match their demand for cost efficiency.City Development PlazaDuring the period, the project recorded a newly contracted area of 7,585 sq.m. and introduced a beauty technology company to enhance the ambience of healthcare business in the building. Retention plans were formulated in light of tenants’ pursuit of cost efficiency, aimed at optimizing product standards to meet tenant needs. The project recorded a renewed leasing area of 2,090 sq.m. and a renewal rate of 68%, retaining tenants including the Guangzhou office of a globally-renowned Contract Research Organisation (CRO).Victory PlazaDuring the period, its anchor tenant, Uniqlo, continued to play a flagship role by launching its C-series products, and hosted the first “A Better Life” campaign of Uniqlo in China, along with gigantic Pokémon installations and A Better Life Music Event, from 28 March to 6 April. Customer flow reached a quarterly peak during the events, driving a 7% year-on-year sales growth in April, and contributing to a 0.3% year-on-year sales growth during the Interim Period. By collaborating with tenants engaged in catering services to capitalize on increased sales with the surge in customer flow, the project drove a year-on-year increase of 0.6% in overall sales during the Interim Period.Shanghai Yue Xiu TowerDuring the period, the project recorded a renewed leasing area of 3,798 sq.m., with a renewal rate of 39%, while securing a newly contracted area of 3,933 sq.m., efficiently making up for the units surrendering ahead of lease expiry. By replacing the energy-saving light tubes in the carpark spaces to enhance brightness, the project enhanced both energy efficiency and service standards, thereby improving tenant satisfaction. As at the end of the Interim Period, the occupancy rate of Shanghai Yue Xiu Tower was 87.2%, representing a year-on-year increase of 2.6 percentage points.Wuhan PropertiesDuring the period, Wuhan Yuexiu Fortune Centre recorded a newly contracted area of 12,395 sq.m., and introduced quality tenants including a member of a leading global automobile group and a diversified professional services company. In addition, it recorded a renewed leasing area of 10,884 sq.m. and a renewal rate of 81%, retaining quality tenants with large leasing areas, including a Fortune Global 500 state-owned enterprise. The business solicitation team optimized the customers’ property visiting experience through partial micro-renovation of units, soft furnishing upgrades and creation of AI model rooms to increase the conversion rate of customers.Starry Victoria Shopping Centre recorded a newly contracted area and renewed leasing area totalling 3,894 sq.m. with a renewal rate of 82% during the period. The project successfully introduced several popular food and beverage brands, including the internet-famous brand “Domino’s” on the 1st floor of Hall A, to attract more family customer groups. The project tapped into nighttime consumption by leveraging the unique appeal of “Joy Garden” on the 4th floor, continuously developing initiatives like “Riverside Starry Night” and “Midnight Diner” to stimulate new sales growth drivers.Hangzhou VictoryHangzhou Victory recorded a newly contracted area of 1,974 sq.m. and introduced a tenant to take up an entire floor during the period. In addition, it recorded a renewed leasing area of 6,083 sq.m. and a renewal rate of 64%, retaining quality tenants including a Fortune Global 500 construction engineering company and the Zhejiang branch of a state-owned enterprise in Shanxi Province.ProspectsThe market generally hopes for further interest rate cuts by the US Federal Reserve in the second half of 2025, though the path and extent remain uncertain. On the other hand, 2025 marks the concluding year of China’s “14th Five-Year Plan”, with policies prioritizing stability, including moderately accommodative monetary policies and “trade-in” consumption subsidy policies aimed at expanding domestic demand to stimulate market vitality. Consequently, the Manager expects the RMB interest rate to remain at a relatively low level. With the accelerated development of new quality productive forces and the advancement of supply-side reforms in China, the Manager expects that new industrial momentum will continue to emerge and business environment will improve. The highly anticipated 15th National Games is scheduled to open in Guangzhou in the second half of 2025, which is expected to boost consumption in shopping malls and demand for hotels and apartments.In the second half of 2025, the Manager will keep abreast of economic development trends and dynamically implement proactive, prudent and flexible leasing strategies, keenly seize potential opportunities, and continuously enhance the market competitiveness of asset portfolio. The Manager will continue to review and make reasonable adjustments to its financing structure depending on expectations of market developments, and introduce low-cost RMB financing through various RMB financing channels to seek more favorable financing costs to offset interest rate risks. Additionally, the Manager will carry out relevant asset appreciation projects as planned, with reasonable planning and phased renovation of the guest rooms at Four Seasons Hotel Guangzhou. By focusing on product enhancement, equipment renewal and safety guarantee, the Manager aims to achieve value preservation and appreciation of the properties and ensure the sound operation of the projects.About Yuexiu Real Estate Investment TrustYuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. The current property portfolio comprises ten high quality properties, namely Guangzhou International Finance Center, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Yuexiu Financial Tower in Guangzhou, Yuexiu Tower in Shanghai, Wuhan Properties in Wuhan (including Wuhan Yuexiu Fortune Centre and Starry Victoria Shopping Centre), Victory Business Centre in Hangzhou and Yuexiu Building in Hong Kong, with a total area of ownership of approximately 1.184 million sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc.For media enquiries:Strategic Financial Relations LimitedVicky LeeTel: +852 2864 4834Email:sprg_yx@sprg.com.hk Phoebe LeungTel: +852 2114 4172 Maggie ZhangTel: +852 2864 4903 Websitehttp://www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.
More